Jacobs & Co. CA decreased its stake in Amgen, Inc. (NASDAQ:AMGN) by 1.6% during the 4th quarter, Holdings Channel reports. The fund owned 39,577 shares of the medical research company’s stock after selling 662 shares during the period. Jacobs & Co. CA’s holdings in Amgen were worth $6,840,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in AMGN. Janus Henderson Group PLC grew its stake in shares of Amgen by 3,664.7% in the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. FMR LLC grew its stake in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Amgen by 40.9% in the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Amgen by 51.8% in the second quarter. Parametric Portfolio Associates LLC now owns 2,299,191 shares of the medical research company’s stock worth $395,990,000 after acquiring an additional 784,957 shares during the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.
Shares of NASDAQ AMGN opened at $168.14 on Friday. The firm has a market cap of $123,936.70, a price-to-earnings ratio of 13.37, a P/E/G ratio of 2.11 and a beta of 1.36. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen declared that its board has initiated a share buyback plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a $1.32 dividend. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.14%. Amgen’s dividend payout ratio is 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $189.75, for a total value of $289,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 4,575 shares of company stock valued at $838,064 over the last ninety days. 0.19% of the stock is currently owned by company insiders.
AMGN has been the topic of several research analyst reports. Morgan Stanley lowered their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a research note on Friday, February 2nd. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $181.60 target price for the company in a research report on Tuesday, February 27th. Oppenheimer reaffirmed a “buy” rating and issued a $205.00 target price on shares of Amgen in a research report on Tuesday, January 30th. Piper Jaffray reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Finally, Goldman Sachs cut Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $190.57.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3340134/amgen-inc-amgn-shares-sold-by-jacobs-co-ca.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.